Literature DB >> 2240479

Successful treatment of disseminated Fusarium infection in an immunocompromised child.

N J Barrios1, D V Kirkpatrick, A Murciano, K Stine, R B Van Dyke, J R Humbert.   

Abstract

We report the first know case of disseminated fungal infection due to Fusarium proliferatum in a bone marrow transplant recipient to our knowledge. Fusarium was cultured from the blood, a paranasal sinus, and necrotic skin lesions. The isolate was sensitive to amphotericin B and on further sensitivity testing, synergy was demonstrated using rifampin in combination with amphotericin B. The patient had this infection while she was receiving alternate-day amphotericin, rifampin, and 5-flucytosine (5-FC) therapy. The infection was documented within 48 h of discontinuing daily granulocyte transfusions, which she had received for 3 weeks. The 5-FC was discontinued when sensitivities showed the organism resistant. After 6 weeks of treatment she showed complete remission of the infection, although neutrophil counts remained below 0.25 X 10(9)/L. From this case and from a review of the literature, it appears that synergic antifungal agents combined with leukocyte transfusions may be beneficial in the successful treatment of fusariosis in the compromised host.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2240479     DOI: 10.1097/00043426-199023000-00013

Source DB:  PubMed          Journal:  Am J Pediatr Hematol Oncol        ISSN: 0192-8562


  12 in total

1.  Three cases of infection with Fusarium species in neutropenic patients.

Authors:  M Nucci; N Spector; S Lucena; P C Bacha; W Pulcheri; A Lamosa; A Derossi; M J Caiuby; J Macieira; H P Oliveira
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-12       Impact factor: 3.267

2.  Fusarium proliferatum soft tissue infection at the site of a puncture by a plant: recovery, isolation, and direct molecular identification.

Authors:  Tara N Palmore; Yvonne R Shea; Richard W Childs; Richard M Sherry; Thomas J Walsh
Journal:  J Clin Microbiol       Date:  2009-11-18       Impact factor: 5.948

3.  Endophthalmitis caused by Fusarium proliferatum.

Authors:  Consuelo Ferrer; Jorge Alio; Alejandra Rodriguez; Mariano Andreu; Francisca Colom
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

4.  Survival after fungemia due to Fusarium moniliforme in a child with neuroblastoma.

Authors:  E Castagnola; A Garaventa; M Conte; A Barretta; E Faggi; C Viscoli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-04       Impact factor: 3.267

5.  Disseminated hyalohyphomycosis caused by a novel human pathogen, Fusarium napiforme.

Authors:  G P Melcher; D A McGough; A W Fothergill; C Norris; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1993-06       Impact factor: 5.948

6.  Less-frequent Fusarium species of clinical interest: correlation between morphological and molecular identification and antifungal susceptibility.

Authors:  Mónica Azor; Josepa Gené; Josep Cano; Palanisamy Manikandan; Narendran Venkatapathy; Josep Guarro
Journal:  J Clin Microbiol       Date:  2009-03-25       Impact factor: 5.948

Review 7.  Fusarium infections in immunocompromised patients: case reports and literature review.

Authors:  M Rabodonirina; M A Piens; M F Monier; E Guého; D Fière; M Mojon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-02       Impact factor: 3.267

Review 8.  Taxonomy, biology, and clinical aspects of Fusarium species.

Authors:  P E Nelson; M C Dignani; E J Anaissie
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

Review 9.  Opportunistic fusarial infections in humans.

Authors:  J Guarro; J Gené
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-09       Impact factor: 3.267

Review 10.  Fusarium infection: report of 26 cases and review of 97 cases from the literature.

Authors:  Maged Muhammed; Theodora Anagnostou; Athanasios Desalermos; Themistoklis K Kourkoumpetis; Herman A Carneiro; Justin Glavis-Bloom; Jeffrey J Coleman; Eleftherios Mylonakis
Journal:  Medicine (Baltimore)       Date:  2013-11       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.